Effectiveness of Individualized Autovaccine Immunotherapy in Women With Recurrent Urinary Tract Infections: A Prospective Cohort Study
Clicks: 1
ID: 314562
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #133 of 208 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Recurrent urinary tract infections (rUTIs) disproportionately affect older women and are frequently driven by non-modifiable risk factors (nmRFs). This study evaluated the effectiveness, safety, and patient-reported outcomes (PROs) of personalized sublingual immunoprophylaxis in women with rUTIs. Methods Prospective, single-center, non-comparative observational cohort study. Women with rUTIs received a Uromune® autovaccine prepared from inactivated strains isolated from each patient’s urine culture (UC). Recurrence episodes and UC results were recorded at baseline and at 3, 9, and 12 months. PROs (daily activity, QAct; emotional distress, QEm) were assessed in a predefined substudy. Longitudinal mixed-effects and population-averaged models evaluated change over time and explored baseline risk factors as effect modifiers. Results Of 119 screened women, 100 were enrolled (median [IQR] age: 73 [61-80] years); most presented multiple nmRFs. Median (IQR) rUTI episodes decreased from 4 (3-5) at baseline to 0 (0-2) at 3 months and remained 1 (0-2) and 1 (0-3) at 9 and 12 months (all p<0.001). Approximately 40% were UTI-free in each follow-up interval. UC negativity was 50.7% at 3 months, decreased at 9 months (25.9%), and increased again at 12 months (45.5%), remaining higher than baseline. QEm improved significantly at 3 and 12 months; QAct showed a trend toward improvement. Vaccine-related adverse events were uncommon (6%) and mild. Conclusions Individualized sublingual immunoprophylaxis was safe and associated with sustained reductions in rUTI episodes, improved microbiological findings, and better emotional well-being, suggesting a potential role as a non-antibiotic preventive strategy. These observational findings are hypothesis-generating and warrant confirmation in controlled studies.
| Reference Key |
openalex_W7162004279
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Vicens Díaz-Brito, Montserrat Sanmartí, Araceli González-Cuevas, Antonio Cárdenas, Maria Eugenia Guerrero, Anna Capella, Eva Martínez-Franco, Montserrat Margarit, Anna Agud, Juan M. Bastarós, Francisco Medina, Encarna Moreno, María Carmen Álvarez, Erika Esteve-Palau |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag315
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.